Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $6.00 -3.85%
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CCEL, MHGU, PLG, More
Revenue Growth %: +17.5%
Financial Fact:
Income (loss) from operations: -653K
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.26 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
- LG Energy 2q Oper Profit 113.3b Won, Est. 210.66b Won - Bloomberg
- Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
